SCHEMBL10269192

SCHEMBL10269192

COC(=O)c1ccc(OC)c(NC(=O)c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.42
PDGFRB P09619 1/20 0.42
MAPT P10636 5/20 0.42
MAPKAPK2 P49137 5/20 0.42
TP53 P04637 3/20 0.42
RXFP1 Q9HBX9 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TNFRSF1A P19438 1/20 0.42
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
HDAC6 Q9UBN7 2/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CDC7 O00311 1/20 0.40
PLK4 O00444 1/20 0.40
AURKA O14965 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10268552 0.92 CYP1A2 (0.45) KDRMAPTMAPKAPK2TP53RXFP1
SCHEMBL10269655 0.91 MEN1 (0.51) MAPTMAPKAPK2TP53RXFP1SMN1; SMN2
SCHEMBL10269041 0.91 KDR (0.43) KDRPDGFRBMAPKAPK2HDAC1CDC7
SCHEMBL10269330 0.90 NPC1 (0.47) KDRMAPTMAPKAPK2RXFP1ALDH1A1
SCHEMBL10269032 0.89 MAPT (0.47) MAPTMAPKAPK2TP53RXFP1SMN1; SMN2
SCHEMBL10269338 0.89 MEN1 (0.48) KDRPDGFRBMAPTMAPKAPK2SMN1; SMN2
SCHEMBL10269034 0.88 ALDH1A1 (0.55) KDRPDGFRBMAPTMAPKAPK2TP53
SCHEMBL758237 0.85 MAPKAPK2 (0.52) KDRPDGFRBMAPKAPK2CDC7PLK4
SCHEMBL10269603 0.84 HPSE (0.53) MAPTTP53RXFP1SMN1; SMN2ALDH1A1
SCHEMBL10269332 0.83 TP53 (0.59) MAPTTP53RXFP1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 KDR 3628/4885PDGFRB 2312/4885MAPT 2375/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 KDR 3628/4885PDGFRB 2312/4885MAPT 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.